Deadly cancers may have a secret weak spot. UCLA scientists discovered that aggressive small cell cancers lacking the RB gene become critically dependent on a protein called E2F3 to survive — and blocking it stops tumor growth. Even better, existing FDA-approved drugs may already be able to exploit this vulnerability, potentially fast-tracking new treatments for cancers that haven't seen major therapeutic advances in decades.
UCLA researchers have uncovered a hidden vulnerability in some of the most aggressive and treatment-resistant cancers — and existing drugs might already be able to exploit it. The study, published in Proceedings of the National Academy of Sciences, focused on small cell neuroendocrine cancers of the lung, prostate, and ovary — fast-spreading tumors that have seen little therapeutic progress in over 50 years.
The key finding: cancer cells that lose a gene called RB (which normally controls cell growth) become critically dependent on a protein called E2F3 to survive. Using CRISPR genome-wide screens, the team showed that removing E2F3 in RB-deficient cells halted tumor growth — a phenomenon known as "synthetic lethality." Since no drugs directly target E2F3, researchers found a workaround: blocking a metabolic enzyme called DHODH lowered E2F3 levels and slowed tumor growth.
Key Takeaways:
Why it matters: These cancers have had essentially unchanged survival statistics for decades. Identifying a druggable vulnerability — especially one that existing approved medications may address — could dramatically accelerate the path to new, effective treatments for patients with very limited options.
